Latest News about NBIX
Recent news which mentions NBIX
Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases
August 05, 2022
From Benzinga
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
August 05, 2022
Tickers
NBIX
From Motley Fool
From Benzinga
From Benzinga
From Benzinga
Tickers
NBIX
From Motley Fool
Neurocrine Biosciences Q1 2022 Earnings Conference Call On May 4, 2022 At 08:00 AM ET
April 25, 2022
Tickers
NBIX
From Benzinga
From Benzinga
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 25, 2022
February 25, 2022
From Benzinga
Looking Into Neurocrine Biosciences's Return On Capital Employed
February 14, 2022
Tickers
NBIX
From Benzinga
Neurocrine Biosciences (NBIX) Q4 2021 Earnings Call Transcript
February 11, 2022
Tickers
NBIX
From Motley Fool
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
February 11, 2022
From Benzinga
Earnings Scheduled For February 11, 2022
February 11, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
February 06, 2022
From Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2022
January 18, 2022
From Benzinga
10 Biggest Price Target Changes For Tuesday
January 18, 2022
From Benzinga
From Benzinga
The Daily Biotech Pulse: Glaukos Gets FDA Nod, Neurocrine Preannounces Soft Ingrezza Sales, 3 IPOs
January 07, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free